The FDA has signed off Compass Therapeutics Inc's (NASDAQ:CMPX) IND application for CTX-009 to initiate a global Phase 2 clinical trial for CTX-009 for advanced Biliary Tract Cancers (BTC) in the U.S. and South Korea.
- The Company plans to include the existing Phase 2 in South Korea in this global study, allowing it to expand the ongoing study of CTX-009 under this IND.
- CTX-009 is a bispecific antibody that simultaneously targets Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A).
- The Phase 2a trial in South Korea is testing CTX-009 combined with paclitaxel in BTC patients.
- The Company said that five partial responses have already been observed among the first 17 patients evaluated, leading to a preliminary overall response rate (ORR) of 29%.
- All patients evaluated have had stable disease or better, with a decline in tumor burden observed in 16 of the 17 patients leading to a Clinical Benefit Rate of 100%.
- Price Action: CMPX shares are down 1.06% at $2.80 during the market session on the last check Thursday.
